EP0028033A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Double-stranded DNA which codes for a polypeptide with human fibroblast interferon activity, cloned DNA, recombinant plasmid containing the DNA and microorganism containing the recombinant plasmid
Assignee: Japanese Foundation for Cancer Research
•
Filing: 1980-10-30
•
Granted: —
•
Expires: 2000-10-30
Abstract
Abstract The invention relates to a DNA which codes for a polypeptide with interferon activity, a cloned DNA showing complementarity to human interferon mRNA, a recombinant plasmid containing such DNA, a microorganism containig the recombinant plasmid and a process for producing said DNA, said cloned DNA, said recombinant plasmid and said microorganism.
Inventors
- 👤 Haruo Sugano
- 👤 Masami Muramatsu
- 👤 Tadatsugu Taniguchi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 16:52
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/565
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
10 words
A DNA which codes for a polypeptide with interferon activity.
Claim 2
Dependent Claim
10 words
A DNA which codes for a polypeptide with interferon activity.
Claim 3
Dependent Claim
10 words
A cloned DNA showing complementarity to human interferon messenger RNA.
Claim 4
Dependent Claim
10 words
A cloned DNA showing complementarity to human interferon messenger RNA.
Claim 5
Dependent Claim
18 words
The cloned DN A according to claim 2, wherein the messenger RNA is human fibroblast interferon messenger RNA.
Claim 6
Dependent Claim
9 words
A cloned DNA which codes for human interferon polypeptide.
Claim 7
Dependent Claim
9 words
A cloned DNA which codes for human interferon polypeptide.
Claim 8
Dependent Claim
15 words
The cloned DNA according to claim 4, wherein the polypeptide is human fibroblast interferon polypeptide.
Claim 9
Dependent Claim
19 words
A recombinant plasmid wherein a DNA showing complementarity to human interferon messenger RNA is inserted in a vector DNA.
Claim 10
Dependent Claim
19 words
A recombinant plasmid wherein a DNA showing complementarity to human interferon messenger RNA is inserted in a vector DNA.
Claim 11
Dependent Claim
17 words
The recombinant plasmid according to claim 6, wherein the messenger RNA is human fibroblast interferon messenger RNA.
Claim 12
Dependent Claim
17 words
The recombinant plasmid according to claims 6 or 7, wherein the plasmid is an Escherichia coli plasmid.
Claim 13
Dependent Claim
18 words
The recombinant plasmid according to claim 8, wherein the plasmid is selected from pBR322, pCRl, pMB9 and pSCl.
Claim 14
Dependent Claim
5 words
The recombinant plasmid TpIF 319-13.
Claim 15
Dependent Claim
5 words
The recombinant plasmid TpIF 319-13.
Claim 16
Dependent Claim
10 words
A microorganism containing the recombinant plasmid defined in claim 6.
Claim 17
Dependent Claim
10 words
A microorganism containing the recombinant plasmid defined in claim 7.
Claim 18
Dependent Claim
11 words
The microorganism according to claim 11 which is Escherichia coli X1776.
Claim 19
Dependent Claim
12 words
The microorganism according to claim 12 which is Escherichia coli X 1776.
Claim 20
Dependent Claim
7 words
E scherichia coli xl776/TpIF 319-13 ATCC 31712.
Claim 21
Dependent Claim
7 words
E scherichia coli xl776/TpIF 319-13 ATCC 31712.
Claim 22
Dependent Claim
18 words
A process for producing a DNA which codes for a polypeptide with interferon activity by recombinant DNA technology.
Claim 23
Dependent Claim
18 words
A process for producing a DNA which codes for a polypeptide with interferon activity by recombinant DNA technology.
Claim 24
Dependent Claim
15 words
The process according to claim 16, wherein the polypeptide is the human fibroblast interferon polypeptide.
Claim 25
Dependent Claim
23 words
A process for producing a DNA which codes for a polypeptide with interferon activity by using human interferon messenger RNA as a template.
Claim 26
Dependent Claim
23 words
A process for producing a DNA which codes for a polypeptide with interferon activity by using human interferon messenger RNA as a template.
Claim 27
Dependent Claim
20 words
The process according to claim 18, wherein the DNA is a cloned DNA showing complementarity to human interferon messenger RNA.
Claim 28
Dependent Claim
16 words
The process according to claim 19, wherein the messenger RNA is human fibroblast interferon messenger RNA.
Claim 29
Dependent Claim
23 words
A process for producing a recombinant plasmid, which comprises inserting a DNA showing complementarity to human interferon messenger RNA in a vector DNA.
Claim 30
Dependent Claim
23 words
A process for producing a recombinant plasmid, which comprises inserting a DNA showing complementarity to human interferon messenger RNA in a vector DNA.
Claim 31
Dependent Claim
16 words
The process according to claim 21, wherein the messenger RNA is human fibroblast interferon messenger RNA.
Claim 32
Dependent Claim
17 words
The process according to claim 21 or 22, wherein the vector DNA is an Escherichia coli plasmid.
Claim 33
Dependent Claim
16 words
The process according to claim.23, wherein the plasmid is selected from pBR322, pCRl, pMB9 and pSCl.
Claim 34
Dependent Claim
13 words
The process according to claim 21, wherein the recombinant plasmid is TpIF 319-13.
Claim 35
Dependent Claim
29 words
A process for producing a microorganism containing a recombinant plasmid defined in claim 21 or 22, which comprises transforming a microorganism with said recombinant plasmid in a conventional manner.
Claim 36
Dependent Claim
14 words
The process according to claim 26, wherein the microorganism is Escherichia coli X 1776.
Claim 37
Dependent Claim
13 words
The process according to claim 26, wherein the recombinant plasmid is TpIF 319-13.
Claim 38
Dependent Claim
21 words
The process according to claim 26, wherein the microorganism containing a recombinant plasmid is Escherichia coli X1776 TpIF 319-13 ATCC 31712.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.